BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31778721)

  • 1. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.
    Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F
    J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based biopharmaceutics modeling of regional and colon absorption in humans.
    Tannergren C; Jadhav H; Eckernäs E; Fagerberg J; Augustijns P; Sjögren E
    Eur J Pharm Biopharm; 2023 May; 186():144-159. PubMed ID: 37028605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches to Account for Colon Absorption in Physiologically Based Biopharmaceutics Modeling of Extended-Release Drug Products.
    Jadhav H; Augustijns P; Tannergren C
    Mol Pharm; 2023 Dec; 20(12):6272-6288. PubMed ID: 37902586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of fasted and fed bioequivalence for immediate release drug products using physiologically based biopharmaceutics modeling (PBBM).
    Jereb R; Kristl A; Mitra A
    Eur J Pharm Sci; 2020 Dec; 155():105554. PubMed ID: 32946959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development.
    Wu D; Li M
    Pharm Res; 2023 Feb; 40(2):321-336. PubMed ID: 36076007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report.
    Mitra A; Suarez-Sharp S; Pepin XJH; Flanagan T; Zhao Y; Kotzagiorgis E; Parrott N; Sharan S; Tistaert C; Heimbach T; Zolnik B; Sjögren E; Wu F; Anand O; Kakar S; Li M; Veerasingham S; Kijima S; Lima Santos GM; Ning B; Raines K; Rullo G; Mandula H; Delvadia P; Dressman J; Dickinson PA; Babiskin A
    J Pharm Sci; 2021 Feb; 110(2):594-609. PubMed ID: 33152375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.
    Tistaert C; Heimbach T; Xia B; Parrott N; Samant TS; Kesisoglou F
    J Pharm Sci; 2019 Jan; 108(1):592-602. PubMed ID: 29906472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.
    Eckernäs E; Tannergren C
    Mol Pharm; 2021 Apr; 18(4):1699-1710. PubMed ID: 33720733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.
    Mackie C; Arora S; Seo P; Moody R; Rege B; Pepin X; Heimbach T; Tannergren C; Mitra A; Suarez-Sharp S; Borges LN; Kijima S; Kotzagiorgis E; Malamatari M; Veerasingham S; Polli JE; Rullo G
    Mol Pharm; 2024 May; 21(5):2065-2080. PubMed ID: 38600804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface.
    Dodd S; Kollipara S; Sanchez-Felix M; Kim H; Meng Q; Beato S; Heimbach T
    J Pharm Sci; 2019 Jan; 108(1):87-101. PubMed ID: 30385285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Physiologically-Based Pharmacokinetic Modeling to Predict Gastric pH-Dependent Drug-Drug Interactions for Weak Base Drugs.
    Dong Z; Li J; Wu F; Zhao P; Lee SC; Zhang L; Seo P; Zhang L
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):456-465. PubMed ID: 32633893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biorelevant in vitro Tools and in silico Modeling to Assess pH-Dependent Drug-drug Interactions for Salts of Weak Acids: Case Example Potassium Raltegravir.
    Segregur D; Mann J; Moir A; Karlsson EM; Dressman J
    J Pharm Sci; 2022 Feb; 111(2):517-528. PubMed ID: 34597624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives.
    Anand O; Pepin XJH; Kolhatkar V; Seo P
    Pharm Res; 2022 Aug; 39(8):1681-1700. PubMed ID: 35585448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Absorption Modeling to Impact Biopharmaceutics and Formulation Strategies in Drug Development-Industry Case Studies.
    Kesisoglou F; Chung J; van Asperen J; Heimbach T
    J Pharm Sci; 2016 Sep; 105(9):2723-2734. PubMed ID: 26886317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
    Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
    J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling.
    Zhu AZ; Ho MD; Gemski CK; Chuang BC; Liao M; Xia CQ
    AAPS J; 2016 Nov; 18(6):1512-1523. PubMed ID: 27600136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.
    Lin W; Chen Y; Unadkat JD; Zhang X; Wu D; Heimbach T
    Pharm Res; 2022 Aug; 39(8):1701-1731. PubMed ID: 35552967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards Virtual Bioequivalence Studies for Oral Dosage Forms Containing Poorly Water-Soluble Drugs: A Physiologically Based Biopharmaceutics Modeling (PBBM) Approach.
    Kambayashi A; Dressman JB
    J Pharm Sci; 2022 Jan; 111(1):135-145. PubMed ID: 34390740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the Relationship of Drug BCS Classification, Food Effect, and Gastric pH-Dependent Drug Interactions.
    Owens K; Argon S; Yu J; Yang X; Wu F; Lee SC; Sun WJ; Ramamoorthy A; Zhang L; Ragueneau-Majlessi I
    AAPS J; 2021 Dec; 24(1):16. PubMed ID: 34961909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.